All In Biotech

Drug Trial Radar · NCT01462136

PK Study of ACHN-490 Injection in Renally Impaired Subjects

A Phase 1 Study To Assess The Pharmacokinetics, Safety, And Tolerability of Intravenous ACHN-490 Injection in Volunteers With Varying Degrees of Renal Dysfunction Compared to Healthy Volunteers

Last checked: Nov 20, 2026Latest source record: Aug 23, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Sep 2011

Primary completion

Not stated

Sponsor

Lead sponsor
Achaogen, Inc.Industry
Sponsor type
Industry
Collaborators
Department of Health and Human Services
First posted
Oct 31, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purposes of this study is to assess the relationship between renal function and pharmacokinetics of ACHN-490 Injection.

Conditions

  • Renal Insufficiency

Interventions

  • ACHN-490 InjectionDrug

    7.5 mg/kg single dose administered intravenously over 30 minutes

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite of PharmacokineticsTime frame: 0-96 hours

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.